---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206360"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:14:42.200674+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints

## Summary
- MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).
- Net loss $206.0M ($1.67/sh) vs $161.4M loss in Q1 2025; cash $1.1B (down $144M from Dec 2025).
- ACACIA-HCM met dual primary endpoints (KCCQ and peak VO2) in non-obstructive HCM; full results at upcoming medical congress.
- Over 275 HCPs prescribed MYQORZO to ~680 patients in Q1; European Commission approved for oHCM.
- FY 2026 GAAP combined R&D and SG&A guidance maintained at $830M-$870M.

## SEC filing metadata
- accession: 0001193125-26-206360
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/0001193125-26-206360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206360
- JSON: https://secwatch.observer/filing/0001193125-26-206360.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206360.txt

## Source-grounded claims
- claim_id: d9a4765fccb4884c30d83fabc108f7ee34529130
  claim: CYTOKINETICS INC reported first quarter of 2026 results: revenue $19.4 million.
  evidence_excerpt: Cash, cash equivalents and investments declined by approximately $144 million during the first quarter of 2026. Revenues • Total revenues for the first quarter of 2026 were $19.4 million, compared to $1.6 million for the same period in 2025. Total revenues in the first quarter of 2026 include: o $4.8 million MYQORZO net product revenue which represents
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/0001193125-26-206360-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.